Scribe BC - Radiation Oncology FU

**DIAGNOSIS** Mrs. Eleanor Vance, a 68-year-old female, was initially diagnosed with Stage IIIB non-small cell lung cancer (NSCLC) in March 2024, with spread to the mediastinal lymph nodes. Initial presentation included a persistent cough, shortness of breath, and a 20-pound weight loss over three months. Baseline laboratory values showed an elevated LDH of 250 and a CEA of 8.2. - Chemotherapy: Four cycles of Carboplatin and Paclitaxel, initiated on 15 April 2024 and completed on 12 July 2024. - Radiation Therapy: Concurrent with chemotherapy, 60 Gy in 30 fractions to the primary lung tumor and mediastinal lymph nodes, completed on 12 July 2024. **INTERVAL HISTORY** I spoke with Eleanor for a follow-up appointment today, 1 November 2024. The visit was conducted with Eleanor present, and her daughter, Sarah, was also present for support. Eleanor reported that she is feeling much better overall, with a significant reduction in cough and improved breathing. She stated that she has regained some of her lost weight and is now eating well. Eleanor reports occasional fatigue, which she manages with rest. She denies any new or worsening symptoms, including chest pain, difficulty swallowing, or neurological changes. We discussed the importance of maintaining a healthy lifestyle, including regular exercise and a balanced diet. I also provided reassurance regarding the potential side effects of radiation therapy and chemotherapy, and the importance of reporting any new symptoms promptly. Most recent laboratory results from 28 October 2024, showed an LDH of 180 and a CEA of 3.1, indicating a positive response to treatment. Previous measurements from 15 July 2024 showed an LDH of 200 and a CEA of 4.5. Eleanor is scheduled for follow-up CT scans of the chest and abdomen in three months, on 1 February 2025, to assess for any recurrence or progression of disease. She was advised to contact the clinic immediately if she experiences any new or concerning symptoms, such as persistent cough, chest pain, or unexplained weight loss. AI CONSENT The patient provided verbal consent to use the AI scribe during this visit, understanding its purpose, potential benefits, and limitations, as well as the need for a temporary audio recording for documentation and associated privacy and security risks.